Miduturu Chandrasekhar V, Deng Xianming, Kwiatkowski Nicholas, Yang Wannian, Brault Laurent, Filippakopoulos Panagis, Chung Eunah, Yang Qingkai, Schwaller Juerg, Knapp Stefan, King Randall W, Lee Jiing-Dwan, Herrgard Sanna, Zarrinkar Patrick, Gray Nathanael S
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Chem Biol. 2011 Jul 29;18(7):868-79. doi: 10.1016/j.chembiol.2011.05.010.
Selective protein kinase inhibitors have only been developed against a small number of kinase targets. Here we demonstrate that "high-throughput kinase profiling" is an efficient method for the discovery of lead compounds for established as well as unexplored kinase targets. We screened a library of 118 compounds constituting two distinct scaffolds (furan-thiazolidinediones and pyrimido-diazepines) against a panel of 353 kinases. A distinct kinase selectivity profile was observed for each scaffold. Selective inhibitors were identified with submicromolar cellular activity against PIM1, ERK5, ACK1, MPS1, PLK1-3, and Aurora A,B kinases. In addition, we identified potent inhibitors for so far unexplored kinases such as DRAK1, HIPK2, and DCAMKL1 that await further evaluation. This inhibitor-centric approach permits comprehensive assessment of a scaffold of interest and represents an efficient and general strategy for identifying new selective kinase inhibitors.
选择性蛋白激酶抑制剂仅针对少数激酶靶点开发。在此我们证明,“高通量激酶谱分析”是一种发现针对既定以及未探索激酶靶点的先导化合物的有效方法。我们针对一组353种激酶筛选了一个由118种化合物组成的文库,这些化合物构成两种不同的骨架(呋喃-噻唑烷二酮和嘧啶并二氮杂卓)。每种骨架都观察到了独特的激酶选择性谱。鉴定出了对PIM1、ERK5、ACK1、MPS1、PLK1 - 3和极光激酶A、B具有亚微摩尔细胞活性的选择性抑制剂。此外,我们还鉴定出了针对迄今未探索的激酶(如DRAK1、HIPK2和DCAMKL1)的强效抑制剂,有待进一步评估。这种以抑制剂为中心的方法允许对感兴趣的骨架进行全面评估,代表了一种识别新型选择性激酶抑制剂的有效且通用的策略。